Trial · NCT07914270
Registered outcomes43
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 43
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Change in Oxidative stress biomarkers (Glutathione Peroxidase Activity) | Pre and post-intervention of 16 weeks | Glutathione peroxidase (GPx) activity will be measured from blood samples as a marker of antioxidant defense. |
| Secondary | Change in Immune system (Total Leukocyte Count) | Pre and post-intervention of 16 weeks | Total circulating leukocyte count will be measured from peripheral blood samples to assess changes in overall immune cell status |
| Secondary | Change in Immune system (Neutrophil Count) | Pre and post-intervention of 16 weeks | Circulating neutrophil count will be measured from peripheral blood samples to assess changes in the neutrophil component of the immune response |
| Secondary | Change in Immune system (Lymphocyte Count) | Pre and post-intervention of 16 weeks | Circulating lymphocyte count will be measured from peripheral blood samples to assess changes in the lymphocyte component of immune function |
| Secondary | Change in Immune system (Monocyte Count) | Pre and post-intervention of 16 weeks | Circulating monocyte count will be measured from peripheral blood samples to assess changes in this component of the innate immune system |
| Secondary | Change in Immune system (Eosinophil Count) | Pre and post-intervention of 16 weeks | Circulating eosinophil count will be measured from peripheral blood samples to assess changes in this leukocyte population |
| Secondary | Change in Immune system (Basophil Count) | Pre and post-intervention of 16 weeks | Circulating basophil count will be measured from peripheral blood samples to assess changes in this leukocyte population |
| Secondary | Change in Immune system (Platelet Count) | Pre and post-intervention of 16 weeks | Circulating platelet count will be measured from peripheral blood samples to assess changes in platelet levels |
| Secondary | Change in Immune system (Neutrophil-to-Lymphocyte Ratio) | Pre and post-intervention of 16 weeks | The neutrophil-to-lymphocyte ratio (NLR) will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. NLR will be used as an integrated hematological marker of systemic inflammatory and immune status. |
| Secondary | Change in Immune system (Systemic Immune-Inflammation Index ) | Pre and post-intervention of 16 weeks | The Systemic Immune-Inflammation Index (SII) will be calculated from peripheral blood platelet, neutrophil, and lymphocyte counts as an integrated marker of systemic immune-inflammatory status. |
| Secondary | Change in Neurobiological function (Brain-Derived Neurotrophic Factor concentration) | Pre and post-intervention of 16 weeks | Circulating brain-derived neurotrophic factor (BDNF) concentration will be measured from blood samples to assess changes in a neurotrophic factor involved in neuronal function and neuroplasticity . |
| Secondary | Change in Cognitive function (Trail Making Test Part A Completion Time) | Pre and post-intervention of 16 weeks | Cognitive performance will be assessed using the Trail Making Test Part A (TMT-A), which primarily evaluates visual attention, processing speed, and visuomotor tracking. Participants will be instructed to connect numbered targets sequentially as quickly and accurately as possible. Completion time will be recorded in seconds, with lower completion times indicating better performance. |
| Secondary | Change in Cognitive function (Trail Making Test Part B Completion Time) | Pre and post-intervention of 16 weeks | Executive and attentional performance will be assessed using the Trail Making Test Part B (TMT-B), which requires participants to alternate sequentially between numbered and lettered targets. The test primarily assesses cognitive flexibility, set-shifting, divided attention, and executive function. Completion time will be recorded in seconds, with lower completion times indicating better performance. |
| Other | Change in WHOQOL-OLD Score | Pre and post-intervention of 16 weeks | Quality of life in older adults will be assessed using the World Health Organization Quality of Life-OLD (WHOQOL-OLD) questionnaire, which evaluates relevant dimensions of quality of life specifically related to older populations. Changes in questionnaire scores will be used to assess the effect on perceived quality of life. |
| Other | Change in Health-Related Quality of Life Assessed by the EQ-5D-5L | Pre and post-intervention of 16 weeks | Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The instrument evaluates health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Changes in EQ-5D-5L health status will be used to assess the effect on perceived health-related quality of life. |
| Other | Change in Pittsburgh Sleep Quality Index Score | Pre and post-intervention of 16 weeks | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), which evaluates different aspects of sleep over the preceding month. Changes in the global PSQI score will be used to assess sleep quality, with higher scores indicating poorer sleep quality |
| Other | Change in Depressive symptoms | Pre and post-intervention of 16 weeks | Depressive symptoms will be assessed using the 9-item Patient Health Questionnaire (PHQ-9). Changes in the total score will be used to assess depressive symptom severity, with higher scores indicating greater severity of depressive symptoms. |
| Other | Change in Fatigue | Pre and post-intervention of 16 weeks | Fatigue will be assessed using the 10-item Fatigue Assessment Scale (FAS). Each item is rated on a five-point response scale ranging from 1 (never) to 5 (always). Changes in the total FAS score will be used to assess perceived fatigue, with higher scores indicating greater fatigue. |
| Other | Change in Affective State | Pre and post-intervention of 16 weeks | Positive affect will be assessed using the Positive Affect subscale of the Positive and Negative Affect Schedule (PANAS). The PANAS comprises 20 affect-related items rated on a five-point response scale. Changes in the Positive Affect subscale score will be used to assess changes in positive emotional state, with higher scores indicating greater positive affect. |
| Other | Change in Serum Creatinine | Pre and post-intervention of 16 weeks | Serum creatinine concentration will be assessed as a clinical safety marker related to renal function. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07914270/registered?page=2